Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects (original) (raw)

Effect of Diltiazem, a Moderate CYP3A Inhibitor, on the Pharmacokinetics of Anacetrapib, a Potent Cholesteryl Ester Transfer Protein Inhibitor, in Healthy Subjects

The Journal of Clinical Pharmacology, 2011

Abstract

Anacetrapib (MK-0859) is a potent and selective inhibitor of cholesteryl ester transfer protein (CETP) currently undergoing development as an oral drug for the treatment of primary hypercholesterolemia and mixed hyperlipidemia. 1-4 A midazolam probe study demonstrated that anacetrapib ...

Amit Garg hasn't uploaded this paper.

Let Amit know you want this paper to be uploaded.

Ask for this paper to be uploaded.